Cabaletta Bio

Cabaletta Bio Reports Promising Data from RESET Trials for Transformative Autoimmune Therapy

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has unveiled new clinical and translational data from its ongoing RESET-Myositisâ„¢, RESET-SLEâ„¢, and RESET-SScâ„¢ trials. The findings highlight potential breakthroughs for rese-cel …

Cabaletta Bio Reports Promising Data from RESET Trials for Transformative Autoimmune Therapy Read More